Successful examples include in vitro experiments performed with EGFR tyrosine kinase (TK) inhibitors, which outlined the role of target mutation and of MET amplification in NSCLC PC-9 cells [46], as well as of Src kinase activation in esophageal squamous cell carcinoma cells [47]. The gene discussed is TKT; the disease is non-small cell lung carcinoma.